Navigation Links
Anthera Presents Data on Varespladib at ATVB Meeting
Date:4/17/2008

SAN MATEO, Calif., April 17 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that Anthera scientists and collaborators have released data from the Varespladib (A-002) clinical and pre-clinical programs at the Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB) Annual Conference in Atlanta, Georgia, held on April 16-18, 2008. Anthera has completed Phase II trials in Varespladib for the treatment of coronary heart disease.
Posters include:

-- Effects of a Selective Secretory Phospholipase A2 Inhibitor on

Low-Density Lipoproteins in CHD Patients with Diabetes.

-- The Synergistic Inhibition of Atherogenesis in ApoE-/- Mice Between

Pravastatin and the sPLA2 Inhibitor Varespladib (A-002).

"We are pleased to see the synergistic effect of Varespladib with statins on plaque reduction, composition and stability in a well established model of atherosclerosis," said Joaquim Trias, Ph.D., Senior Vice President of Preclinical Development at Anthera Pharmaceuticals, Inc.

"Along with the Phase II PLASMA data presented at ACC earlier this year, today's announcement gives us added confidence as we move the Varespladib clinical program forward," said Dr. James E. Pennington, M.D., Executive Vice President and Chief Medical Officer of Anthera Pharmaceuticals, Inc. "These findings further support our clinical development program as we begin Phase III clinical trials in patients with acute coronary syndromes where inflammation, atherosclerosis and cholesterol levels are highly correlated with outcomes."

Anthera Pharmaceuticals is a privately-held company committed to developing and commercializing clinical pharmaceutical products that address unmet medical needs of patients with life-threatening, chronic and acute inflammatory diseases and autoimmune disorders. The Company has acquired from Eli Lilly and Company and Shion
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Anthera Pharmaceuticals Forms Scientific Advisory Board
2. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
3. Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research
4. ProMetic presents preclinical data for prostate and pancreatic cancer at the AACR Meeting
5. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect
6. Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR
7. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
8. SGX Presents Preclinical MET Data at AACR
9. ARIUS presents new findings for anti-cancer antibody programs at AACR
10. Ardea Presents Preclinical Data on Novel Next Generation Non-Nucleoside Reverse Transcriptase Inhibitors Demonstrating Potent Anti-HIV Activity Against Resistant Viruses
11. MedImmune Presents Data Highlighting its Progressive Oncology Portfolio at Annual Meeting of the American Association For Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014  Dyadic International, Inc. ("Dyadic") ... patented and proprietary technologies are used to discover, ... for the bioenergy, bio-based chemical, biopharmaceutical and industrial ... "Tom" Dubinski as Vice President and Chief Financial ... financial and information technology operations for Dyadic and ...
(Date:7/30/2014)... July 30, 2014  AtheroNova Inc. (OTCBB: AHRO), ... development of compounds to safely regress atherosclerotic plaque ... that its partner, CardioNova, has accomplished first dosing ... with AtheroNova,s lead compound, AHRO-001.  This Phase 1b ... Phase 1 safety trial completed in February 2014, ...
(Date:7/30/2014)... 2014 Connecticut Center for Advanced Technology, ... East Hartford, Conn., was awarded a Rural Business Enterprise ... project that will determine the feasibility of implementing an ... USDA Rural Development provided $53,000 for CCAT under the ... phase of the feasibility study in fiscal year 2014. ...
(Date:7/30/2014)... July 30, 2014 Immunology ... leading Immunologists, Principle Investigators, scientists in the field, ... Malemud, Professor at Case Western Reserve University School ... keynote address on “The effects of recombinant ... of matrix metalloproteinase-9”. Arya Biragyn, a Senior investigator ...
Breaking Biology Technology:Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 2USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 3Unveiling Breakthroughs in Clinical & Cellular Immunology 2Unveiling Breakthroughs in Clinical & Cellular Immunology 3
... Revenue Increased 61% Compared to 3Q06 to $43.5 Million in 3Q07 -,- 3Q07 ... ... Share - - Company Provides Financial ... Oriental,Bioengineering, Inc. (NYSE: AOB ), a leading manufacturer and distributor of,plant-based pharmaceutical ...
... ... up 10%, Compared to Third Quarter 2006 FFO Per Share (Diluted) of ... $1.32 - Third Quarter 2007 Total Revenues up 23%, FFO Available to ... Stockholders up 21% - Third Quarter 2007 Earnings Per Share (Diluted) ...
... Bruker Daltonics today,announced the availability of its ... poster presentations on its website at, http://www.bdal.com . ... Characterization and General Mass Spectrometry, -- Novel ... Peptide Characterization Poster M103 ...
Cached Biology Technology:American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 2American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 3American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 4American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 5American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 6American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 7American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 8Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 2Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 3Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 4Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 5Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 6Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 7Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 8Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 9Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 10Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 11Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 12Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 13Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 14Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 15Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 16Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 17Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 18Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 19Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 20Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 21Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 22Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 23Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 24Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 25Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 26Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 27Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 28Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 29
(Date:7/30/2014)... map of the carbon stocks stored on land ... and improved methodology used to make the map ... economies. The new carbon map also reveals ... the critical input to studies of deforestation and ... purposes. The technique includes the determination of uncertainty ...
(Date:7/29/2014)... and applications for imaging and manipulation of the brain ... the inspiration behind Neurophotonics , a new peer-reviewed ... and photonics. , The first issue coincides with the ... and a special section features articles that lay out ... that optics and photonics will have on advancing our ...
(Date:7/29/2014)... a restaurant, don,t blame yourself; blame the menu. What ... want and more to do with a menu,s layout and ... over 300 diners, the Cornell study published this month in ... when it comes to what you order for dinner, two ... how you imagine it will taste. , First, any food ...
Breaking Biology News(10 mins):Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3SPIE launches Neurophotonics journal with special section on BRAIN Initiative 2SPIE launches Neurophotonics journal with special section on BRAIN Initiative 3Menu secrets that can make you slim by design 2
... University scientists are working to determine how neurons are ... disorders like Tuberous Sclerosis Complex (TSC). TSC is ... tumors in the brain and other vital organs and ... impairment that may arise from the abnormal generation of ...
... who invest in their own solar panels for the roof ... the long term but how long will this technology ... up to 25 years to their customers, the manufacturers themselves ... modules must fulfill certain standards, of course, to be approved ...
... fundamental processes in the life of plants because they have ... Leeds researchers. Arabidopsis thaliana also known as thale ... over Europe and Asia, but the small white flower leads ... world. It has become the dominant "model plant" in ...
Cached Biology News:Clemson University study points to possible treatment for brain disorders 2Predicting the life expectancy of solar modules 2Predicting the life expectancy of solar modules 3Model plant misled scientists about multicellular growth 2Model plant misled scientists about multicellular growth 3
...
Lyophilized. Purity: ≥90% by electrophoresis. Reconstitute in 0.3% NaCl. Prepared from serum that has been shown by certified tests to be negative for HBsAg and for HIV and HCV antibodies. ...
Porcine Pulmonary Artery Endothelial Cells (PPAEC) (>500,000 cells)...
PP2B-Abeta (C-20)...
Biology Products: